B
Burning Rock / 燃石医学
Guangzhou Nasdaq oncology NGS diagnostics OEM (OncoScreen / OncoCompass)
About Burning Rock / 燃石医学
Burning Rock / 燃石医学 (Burning Rock Biotech; Nasdaq BNR) is a Guangzhou Nasdaq-listed oncology NGS diagnostics OEM founded in 2014 on International Bio Island. The company develops OncoScreen and OncoCompass tissue and liquid-biopsy panels plus biopharma CDx and clinical-trial NGS services spanning China and US labs. It supports hospitals and pharma with therapy-selection and trial enrollment genomics rather than pure consulting. Mid-size China NGS kit leftover beyond GenePlus FIX, Pack 39 AmoyDx FIX, and MGI mega — city-level Guangzhou HQ, employees band 501-1000 from Nasdaq YE-class headcount.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Guangzhou, China
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Burning Rock / 燃石医学 in the Guangzhou ecosystem
The Burning Rock / 燃石医学 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
NLVC
Legend Star
LYFE Capital
HSG- CICMB International
Series B and later3 investors entered at this stage
GIC
Lilly Asia Ventures- TCTaihe Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Burning Rock / 燃石医学 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Burning Rock / 燃石医学 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

